



The Medicines Patent Pool

September, 2021

Mission

Increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries (LMICs) through voluntary licensing and patent pooling.

Vision

A world in which people in need in LMICs have rapid access to effective and affordable medical treatments and health technologies.

We work with a range of partners — civil society, international organisations, industry, patient groups and governments — to prioritise and license novel and existing medicines and health technologies for people in these countries.

MPP is public health organization established in 2010 to accelerate **access to new HIV medicines** in LMICs

...and to facilitate the **development of new formulations needed in developing countries**

Operates through **voluntary licences** to facilitate early entry of **generic manufacturers** in LMICs

Expanded to work on **hepatitis C, TB (2016)** and other **patented essential medicines (2018)**....and now COVID-19



The MPP is funded by:



and



MPP licences enable additional manufacturers to enter LMIC markets before patent expiry, facilitating competition and price reductions, under agreed terms



Innovators



Key
stakeholders



Manufacturers



Access



Royalties where
appropriate

Guiding Principles

- ✓ Public health driven
- ✓ Transparent

- ✓ Focus on accelerating access
- ✓ Non-exclusive

- ✓ Flexible
- ✓ Voluntary

PATENT HOLDERS

Effective and impactful way to make innovative products available in resource-limited settings; complements commercial strategy; reputational benefits; royalties

LOW-COST PRODUCERS

Accelerated approach to the development of affordable versions of health technologies needed in LMICs; where needed, possibility to develop products adapted to specific LMIC needs (e.g. new formulations of existing medicines)

GOVERNMENTS, TREATMENT PROVIDERS

Ability to stretch budgets to treat (prevent/diagnose) more people with improved products at more affordable prices

COMMUNITIES

Greater access to quality, appropriate, affordable and life-saving health technologies

2010-2020

WHAT HAS MPP ACHIEVED SO FAR?

abbvie

 **Boehringer
Ingelheim**


Bristol-Myers Squibb


GILEAD

janssen 

 **MSD**

 **NIH**

lopinavir
ritonavir
(adults)

nevirapine
(non-assert)

atazanavir

bictegravir
cobicistat

darunavir
(paediatric;
non-assert)

raltegravir
(paediatric)

darunavir
related

lopinavir
ritonavir
(paediatrics)

elvitegravir
emtricitabine
tenofovir alafenamide
tenofovir disoproxil

 **ViiV
Healthcare**

 **Roche**

 **UNIVERSITY OF
LIVERPOOL**

abbvie


Bristol-Myers Squibb

 **PHARCO
CORPORATION**

 **JOHNS HOPKINS
UNIVERSITY**

 **Pfizer**

abacavir
(paediatrics)

valganciclovir
(pricing agreement)

solid drug
nanoparticles
technology

glecaprevir/
pibrentasvir

daclastavir

ravidasvir

sutezolid

dolutegravir
(paediatrics)

dolutegravir
(adults)

49.7
MILLION

PATIENT-YEARS
OF TREATMENTS*

18.6
BILLION


DOSES SUPPLIED BY MPP
LICENSEES SINCE 2012*

73%
AVERAGE DROP

IN FORMULATION PRICES AFTER
MPP'S AGREEMENTS*
ACROSS 143 COUNTRIES

\$1.96
BILLION USD


IN SAVINGS*



Equivalent to treating
nearly
6X
the population
of New York City¹



Over
2 doses
provided to
every person
in the
WORLD




More than
the annual
health care
expenditure of
BRAZIL³

*Impact of MPP agreements until June 2020 by KPMG (HIV, HCV products):

¹<https://worldpopulationreview.com/world-cities/> ²<https://www.worldometers.info/world-population/> ³WHO, Global Health Expenditures database (2017)

MPP in COVID-19

On March 30, 2020, the MPP Board agreed to temporarily expand its mandate

“to include any **health technology** that could contribute to the global response to COVID-19 and where licensing could facilitate innovation and access.

With the support of Unitaid, this will allow MPP to offer its IP and licensing expertise to the World Health Organization (WHO) to assist the global effort in any way it can.”

- Collaborating partner in the **Access to COVID-19 Tools Accelerator** (ACT-A) therapeutics pillar to facilitate affordable access to new treatments
- Implementing partner of C-TAP, the **COVID-19 Technology Access Pool**, led by WHO and endorsed by 43 Member States
- At request of WHO, tracking patents on COVID-19 treatments in **MedsPaL** (www.medspal.org) and in June 2021 launched **VaxPaL**, with patents on COVID-19 vaccines
- 21 generic manufacturing companies joined MPP in an **Open Pledge** committing to making new COVID-19 treatments (November 2020)
- MPP in **discussions / negotiations** with several developers of COVID-19 treatments, diagnostics and vaccines.
- MPP supporting WHO and South African partners to establish the first **mRNA technology transfer hub**

Aims to create a global tech transfer hub / recipients network

Envisioning a global network of technology transfer hub(s) / recipients dedicated to LMIC uptake




Centralized hub(s) to facilitate multilateral technology transfers to regionally distributed LMIC recipients



LMIC recipients acquire technology and rapidly scale up production during pandemics



Recipient facilities pursue sustainable business models between pandemics



Next Steps Hub Implementation



Technology
selection



SA Hub
implementation



Funding



Workforce
training



Other hub /
recipients'
selection

Key Partners South Africa Hub



BIOVAC
science of protecting life



Partners in Latin America





medicines
patent
pool



THANK YOU